Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT316 in Advanced Solid Tumors (Gynecological Tumors)
NCT06145802Withdrawn
- Sponsor
- Grit Biotechnology
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Open-label, single-arm trial of GT316 in solid tumor, sponsored by Grit Biotechnology. Primary endpoint: Incidence and severity of adverse events per CTCAE 5.0 at 3 years. Planned start Mar 2023; status: withdrawn.
02
Drugs
GT316
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06145802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145802.